A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs ART I02 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Arthrogen
- 27 Jun 2017 Planned number of patients changed from 15 to 12.
- 27 Jun 2017 Status changed from not yet recruiting to recruiting.
- 16 Feb 2017 Results from this trial are expected by the end of 2018, according to an Arthrogen media release.